GLP-1 & BEYOND — SOURCES, IMAGE CREDITS AND VISUAL NOTES Music: Floating Cities — Kevin MacLeod (incompetech.com). Licensed under Creative Commons Attribution 4.0. https://creativecommons.org/licenses/by/4.0/ Music has been edited, looped, faded and mixed underneath narration. Novo Nordisk headquarters: News Øresund / Johan Wessman. https://www.flickr.com/photos/newsoresund/29190030262 CC BY 3.0: https://creativecommons.org/licenses/by/3.0/ Image cropped and animated. Eli Lilly headquarters: Paul Sableman. https://www.flickr.com/photos/pasa/5470479848 CC BY 2.0: https://creativecommons.org/licenses/by/2.0/ Image cropped and animated. Novo Nordisk research and product photographs: official media library. https://www.novonordisk.com/news-and-media/media-library.html https://www.novonordisk-us.com/media/media-library.html These are rights-reserved assets under the library's reuse terms, not open-source photographs. Official terms permit noncommercial reporting/research; obtain permission for advertising, commercial or monetized uses outside those terms. Selected historical product formats are shown; availability and indications differ by country. Molecular illustrations: PDB 1D0R (GLP-1 NMR conformer in TFE/water); PDB 7FIM and 7VAB (tirzepatide receptor complexes); PDB 8YW3, 8YW4, 8YW5 (retatrutide receptor complexes). Molecular motion is illustrative rather than a simulation of observed dynamics. Sizes are not to scale. Some microscopic footage was AI-generated. Anatomical and absorption sequences are educational conceptual illustrations, not actual recordings, quantitative simulations, or injection instructions. The new tissue-to-circulation sequence illustrates extracellular movement toward a capillary; lymphatic uptake can also contribute. Absorption and clearance differ between medicines. Keep these credits with the video, such as in the YouTube description/reference section. Scientific evidence and self-reported observations are distinct. WPF does not sell peptides or provide medical advice. AMYLIN / CAGRISEMA REPLACEMENT SEQUENCE The 3:22–3:49 section uses a paid AI-generated cinematic illustration, with locally added medicine labels and a gentle held ending. Amber and blue ribbons represent cagrilintide and semaglutide acting through distinct receptor pathways. Cagrilintide is a long-acting amylin analogue; semaglutide is a GLP-1 receptor agonist; CagriSema combines these distinct medicines, rather than fusing them into one molecule. The membrane and receptor shapes are conceptual artwork, not experimentally resolved atomic structures, actual microscopy, or simulated binding dynamics. No clinical efficacy, safety, or regulatory status is established by the imagery. Scientific background: Cao et al., Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications 16, 3389 (2025). https://doi.org/10.1038/s41467-025-58680-y Zhang et al., Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Reports 36, 109374 (2021). https://doi.org/10.1016/j.celrep.2021.109374 These references inform the pathway explanation; the new cinematic footage was not rendered from their structural coordinates. WORLDWIDE FIELD — DISCOVERY, APPROVAL AND ACCESS Three AI-generated editorial illustrations depict research discovery, regulatory evidence review, and medicine access/affordability. Anonymous people and settings are fictional. The approval checkmark is a symbolic illustration, not an official regulator seal or proof of approval of any named medicine. The euro motif represents cost and affordability; it does not imply access is limited to Europe. These images do not depict actual historical events or a particular clinical study. NEXT FRONTIER — 4:28 VISUAL AI-generated editorial concept artwork shows an imagined microfluidic research chip and abstract peptide/receptor motifs. It is not an actual laboratory photograph, exact molecular structure, experimental result, or visualization of a specific five-target medicine. The retained text distinguishes the mouse study from the separate rat study, and states that animal findings do not establish human safety or effectiveness. CLOSING BRANDING The globe branding animation was supplied by WPF. It replaces the previous ending from 4:41 onward. Narration closes after “World Peptide Foundation”; music then takes over, fading out at 4:59. The original artwork is fitted without stretching or cropping its wordmark; a clean dark navy background fills the side areas of the widescreen frame, replacing the former blurred borders. The final branding image is held through the end. No new video generation was used for this ending edit. PUBLICATION CLEANUP AND RIGHTS STATUS The approved 4:59 timing and soundtrack are retained. Scientific qualifications were enlarged. At WPF's request, on-screen AI-illustration labels were removed; the production disclosures remain in these notes. At YouTube upload, select Yes for AI use / altered or synthetic content; that upload setting has not been applied by this local edit. Photo permissions remain unconfirmed for the retained Habener, Mojsov, Drucker and John Eng portraits, and for the exact Bronx VA photograph used. The Holst source image contains a copyright notice identifying photographer Ricky John Molloy; a reuse grant for that specific photograph is not recorded. Attribution alone does not supply permission. Novo's official research/product-library terms are noncommercial; monetized use is not confirmed. See GLP1-Beyond-Publication-Notes.md for the asset-by-asset record. The film should not be described as fully rights-cleared on this basis. The Boston map marker was checked against its renderer coordinates: -71.06, 42.36. Its position was retained. The source movie remains native 1280x720; no claim of recovered 1080p source detail is made. REALISTIC ORGAN REPLACEMENT — 2:41.25–2:55.25 The pancreas, stomach and brain artwork was replaced with new AI-generated lifelike anatomical illustrations, composited into the existing educational scene design with gentle zoom motion. These are illustrative depictions, not patient photographs, surgical footage, medical scans, diagnostic images or physiological simulations. Natural tissue colors and textures replace the previous smooth/glossy organ models. The original explanatory wording, narration and organ-change timing are retained. The organs are shown separately, not at a common scale or in their in-body positions. No Runway generation was used for this change. ENHANCED MOLECULAR MODELS — 2:55.25–3:22 The approved gold-peptide / teal-receptor space-filling style replaces the former thin backbone models. Tirzepatide is shown with GLP-1R (PDB 7FIM) and GIPR (PDB 7VAB). Retatrutide is shown separately with GLP-1R (PDB 8YW3), GIPR (PDB 8YW4) and GCGR (PDB 8YW5). Each view uses its corresponding experimental coordinate set, with receptor chain R and peptide chain P; G proteins and stabilizing nanobodies are omitted for clarity. Display radii, colors, lighting and gentle zoom motion are illustrative. These are bound structural snapshots, not actual microscopy or simulations of binding or receptor activation. Only resolved atoms are shown; missing chemical groups or residues are not invented. The 7VAB structure uses a non-acylated tirzepatide construct, identified on screen. Experimental constructs and missing regions mean these views should not be taken as complete chemical depictions of the marketed medicines. The narration and section timing are retained. Structure sources: https://www.rcsb.org/structure/7FIM https://www.rcsb.org/structure/7VAB https://www.rcsb.org/structure/8YW3 https://www.rcsb.org/structure/8YW4 https://www.rcsb.org/structure/8YW5 Tirzepatide structural paper: Zhao et al., Nature Communications 13, 1057 (2022), https://doi.org/10.1038/s41467-022-28683-0 No paid AI or video generation was used for this molecular-model replacement.